Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is an immunoglobulin presented as a sterile liquid for intravenous use. It provides passive immunity by supplying exogenous IgG antibodies and is used in patients with immune deficiencies or certain immune‑mediated disorders. GNH USA supplies Nanogam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nanogam is an intravenous immunoglobulin used to replace or augment antibodies in several immune‑related conditions. - Primary immunodeficiency diseases: supplies IgG to reduce the frequency and severity of infections. - Secondary immunodeficiency (e.g., after bone‑marrow transplant or chemotherapy): restores antibody levels to support immune function. - Immune thrombocytopenic purpura (ITP): modulates the immune response to increase platelet counts. - Kawasaki disease: reduces inflammation and coronary artery complications in children.

Nanogam may cause a range of adverse reactions, most of which are related to the infusion process or the immunoglobulin content.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typically occurring during or shortly after infusion. - Fatigue: a feeling of tiredness that may last several hours. - Nausea or vomiting: gastrointestinal discomfort during infusion. - Infusion‑related reactions: erythema, itching, or mild hypotension. - Muscle aches: occasional soreness after treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation that can affect veins or arteries. - Acute renal failure: sudden loss of kidney function, especially in high‑risk patients. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: markedly low platelet counts increasing bleeding risk.

Before initiating Nanogam therapy, clinicians should consider several safety measures. - Baseline assessment: evaluate serum IgG levels and infection history. - Renal monitoring: check kidney function regularly, especially in patients with pre‑existing renal disease. - Infection screening: rule out active infections prior to infusion. - Aseptic technique: ensure sterile handling of the product to prevent contamination. - IgA deficiency: avoid in patients with anti‑IgA antibodies due to risk of severe reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine effectiveness and increase infection risk. - Rituximab: B‑cell depletion can diminish the therapeutic benefit of IVIG. - High‑dose cytotoxic chemotherapy: may exacerbate immunosuppression and infection susceptibility.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase risk of hypertension and fluid retention. - Diuretics: combined use can affect renal function and electrolyte balance. - ACE inhibitors or ARBs: monitor for additive renal impairment, especially in patients with compromised kidney function.